BTIG lowered the firm’s price target on OrthoPediatrics (KIDS) to $39 from $40 and keeps a Buy rating on the shares after its Q2 results. Trauma & Deformity – T&D – performance was soft in the quarter, but this was offset by an 11.6% beat within Scoliosis, while gross margin and operating margin missed the Street by 170bps and 720bps, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- OrthoPediatrics Corp. Achieves Record Revenue Milestone
- OrthoPediatrics Highlights Strategic Focus in Presentations
- OrthoPediatrics reports Q2 EPS (11c), consensus (28c)
- OrthoPediatrics raises FY25 revenue view to $237M-$242M from $236M-$242M
- OrthoPediatrics Expands Specialty Bracing Division Globally